[Skip to Content]
[Skip to Content Landing]
April 23, 1982

Modified antigen therapy aids allergy victims

JAMA. 1982;247(16):2202-2203. doi:10.1001/jama.1982.03320410008003

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Desensitization therapy for ragweed hay fever may become more effective and safer with newer forms of reagents, according to results presented at this year's meeting of the American Academy of Allergy and Immunology in Montreal.

Furthermore, since effective desensitization is achieved with a much shorter course of these preparations, called modified antigens, the cost to the patient will be greatly reduced when they come on the market.

The Food and Drug Administration is expected to approve modified antigens in the next few years. Their availability may extend the benefits of ragweed immunotherapy to many more of the estimated 15 million sufferers in the United States.

Clinical Studies With Modified Antigens  Roy Patterson, MD, and colleagues in the Department of Medicine at Northwestern University Medical School in Chicago have been working with a polymerized ragweed (PRW) antigen preparation for a number of years (JAMA [MEDICAL NEWS] 1980;243:1703-1704). At this year's meeting